
Government services provider Maximus (NYSE:MMS) met Wall Street’s revenue expectations in calendar Q3 2026 [fiscal Q4 2026], but sales fell by 1.3% year on year to $1.30 billion. The company’s full-year revenue guidance of $5.55 billion at the midpoint came in 3.2% above analysts’ estimates. Its non-GAAP profit of $2.11 per share was 14.1% above analysts’ consensus estimates.
Is now the time to buy Maximus? Find out in our full research report (it’s free for active Edge members).
Maximus delivered results in line with Wall Street’s revenue expectations for the third quarter, but the market responded negatively to the company’s performance and outlook. Management pointed to operational improvements, higher-margin contract renewals, and the benefits of technology investments, particularly in automation and AI-enabled solutions, as key factors supporting margins and profitability. CEO Bruce Caswell emphasized that disciplined execution helped mitigate headwinds from contract modifications and temporary declines in clinical volumes, while also noting the impact of a pause in incentives for the Veterans Affairs Medical Disability Examination program.
Looking ahead, the company’s guidance reflects both optimism around its recent Agile Defense acquisition and caution regarding upcoming shifts in contract structures and government policy. Management expects growth to be driven by expanded defense and national security offerings, as well as continued focus on program integrity and technology-enabled solutions. However, CFO David Mutryn cautioned that the absence of prior-year incentive payments and the evolving landscape in core government services could weigh on near-term earnings, stating, "Our outlook assumes no incentive contribution on our VA MDE work, and we have taken a conservative approach to federal segment growth."
Management cited the integration of Agile Defense, strong contract renewal wins, and a focus on technology-driven efficiency as key contributors to the quarter’s results and strategic positioning.
Maximus’ outlook is shaped by the integration of Agile Defense, demand for program integrity solutions, and the transition of key government contracts impacting both revenue and margins.
In upcoming quarters, our team will monitor (1) Agile Defense’s integration progress and its ability to drive double-digit growth, (2) the impact of new state and federal contract structures—especially the VA MDE transition—on margins and volume allocation, and (3) adoption of AI-enabled solutions by government customers. Execution on these priorities and signs of improved contract momentum outside the U.S. will be key data points.
Maximus currently trades at $61.99, down from $65.26 just before the earnings. At this price, is it a buy or sell? See for yourself in our full research report (it’s free).
WHILE YOU’RE HERE: Top 9 Market-Beating Stocks. The best stocks don’t just beat the market once. They do it again. And again. Robust revenue growth, rising free cash flow, returns on capital that leave their competition in the dust. The market has already rewarded these businesses.
But our AI platform says the party isn’t over. Find out which 9 stocks made the cut this week, free. Get Our Top 9 Market-Beating Stocks for Free HERE.
Stocks that have made our list include now familiar names such as Nvidia (+1,460% between June 2020 and June 2025) as well as under-the-radar businesses like the once-micro-cap company Kadant (+214% between June 2020 and June 2025). Find your next big winner with StockStory today.